AstraZeneca, Leo Pharma deal
AstraZeneca granted Leo exclusive, worldwide rights to tralokinumab ( CAT-354) for dermatological indications and exclusive, European rights to brodalumab ( KHK4827). For tralokinumab, AZ will receive $115 million up front and up to $1 billion in commercial milestones, plus up to mid-teen tiered royalties. AZ will retain rights to tralokinumab in non-dermatology indications and supply the product to Leo. The companies expect the deal for tralokinumab to close next quarter. Tralokinumab, a human IgG4 mAb against IL-13, completed Phase IIb testing to treat atopic dermatitis.
For brodalumab, AZ said it granted Leo rights under terms “similar” to its deal with Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX, Laval, Quebec). AZ and Valeant terminated the European portion of a deal granting Valeant rights to develop and commercialize the human IgG2 mAb against IL-17 receptor (IL17R; IL17RA) outside of Japan and other Asian territories. Brodalumab is under EMA review to treat moderate to severe plaque psoriasis. ...